Amylin and Glucagon-Like Peptide-1 (GLP-1): Influence on Gastric Emptying, Appetite and Food Intake in Humans
NCT00876213 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 23
Last updated 2009-04-06
Summary
The aim of this proposal is to dissect the mechanisms controlling gastric emptying, appetite and food intake in humans, and to obtain new knowledge to fight obesity on a pharmacological basis.
Conditions
Sponsors & Collaborators
-
Amylin Pharmaceuticals, LLC.
collaborator INDUSTRY -
Hvidovre University Hospital
lead OTHER
Principal Investigators
-
Meena Asmar, MD,Ph.Dstud. · Panum Institut
-
Jens Juul Holst, Professor,MD · Panum Institut
Eligibility
- Min Age
- 18 Years
- Max Age
- 50 Years
- Sex
- MALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2007-03-31
- Completion
- 2008-06-30
Countries
- Denmark
Study Locations
More Related Trials
-
GIP and GLP-1 on Gastric Emptying, Appetite and Insulin-glucose
NCT01079624 ·Status: COMPLETED ·Phase: PHASE1
-
The Interaction Between Appetite Hormones
NCT02094183 ·Status: COMPLETED ·Phase: NA
-
Intact Vagal Innervation and Glucagon-like Peptide-1 (GLP-1) Effects
NCT01176890 ·Status: UNKNOWN ·Phase: NA
-
GLP-1 Response and Effect in Individuals With Obesity Causing Genetic Mutations
NCT02082496 ·Status: COMPLETED ·Phase: PHASE2
-
The Importance of Glucagon-Like Peptide-2 (GLP-2)in Mesenteric Bloodflow in Humans
NCT00273000 ·Status: UNKNOWN ·Phase: NA
-
Intestinal Glucagon-like Peptide-1 (GLP-1) and the Physiological Role in Eating in Humans
NCT01900340 ·Status: COMPLETED ·Phase: PHASE1
-
Blocking of the Gut Hormone Receptor for Glucagon-like Peptide 2 (GLP-2) by the GLP-2 Receptor Antagonist GLP-2(3-33)
NCT06774807 ·Status: COMPLETED ·Phase: NA
-
GLP-1 Inhibits Prandial Antro-duodeno-jejunal Motility in Humans
NCT02731664 ·Status: COMPLETED ·Phase: PHASE1
-
The Effect of GLP-1 on the Inhibition of Glucagon Secretion
NCT01507597 ·Status: COMPLETED ·Phase: NA
-
Co-infusion of Neurotensin and GLP-1 Effects on Appetite and Food Intake.
NCT04186026 ·Status: UNKNOWN ·Phase: NA
-
Effect of the Enteric Hormone Glucagon-Like Peptide (GLP-2) on the Intestinal Blood Flow in Patients With Short Bowel Syndrome
NCT00673751 ·Status: UNKNOWN ·Phase: NA
-
The Effect of Liraglutide Treatment on Postprandial Chylomicron and VLDL Kinetics, Liver Fat and de Novo Lipogenesis
NCT02765399 ·Status: COMPLETED ·Phase: PHASE4
-
To Determine Tolerability to Glucagon Infusion in Obese Subjects
NCT02817659 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
The Role of Amylin and Incretins on Postprandial Metabolisms in Adolescents With Type 2 Diabetes Mellitus (T2DM).
NCT00361946 ·Status: COMPLETED
-
Effects of Intravenous Infusions of Gut Hormones on Appetite and Metabolism.
NCT00940134 ·Status: COMPLETED ·Phase: NA
-
GLP-1's Effect on Cardiac Parameters and Mesenteric Blood Flow
NCT01988545 ·Status: UNKNOWN ·Phase: NA
-
-Oleoyl Glycerol is a GPR119 Agonist and Signals GLP-1 Release in Humans.
NCT01043445 ·Status: COMPLETED ·Phase: NA
-
The Role of Metformin and Colesevelam in Human GLP-1 Secretion
NCT02050074 ·Status: COMPLETED ·Phase: PHASE4
-
Separate and Combined Extrapancreatic Effects of the Incretin Hormones
NCT05177653 ·Status: COMPLETED ·Phase: NA
-
Hyperglycemia and the Extra-pancreatic Effect of Incretins
NCT01749163 ·Status: COMPLETED ·Phase: NA
-
Glucagon Like Peptide 1 (GLP-1) Booster™ RCT Study
NCT07141472 ·Status: COMPLETED ·Phase: NA
-
GLP-1 Signaling in Truncally Vagotomized Subjects
NCT02940184 ·Status: UNKNOWN ·Phase: NA
-
Glucagon-like Peptide 2 - a Glucose Dependent Glucagonotropic Hormone?
NCT03954873 ·Status: COMPLETED ·Phase: NA
-
The Effect of GIP, GLP-1 and GLP-2 in Individuals With Genetically Altered Receptor Function
NCT06194955 ·Status: COMPLETED ·Phase: NA
-
Effects of Glucagon Like Peptide-1(GLP-1) and Liraglutide on Brain Satiety and Reward Circuits and Feeding Behavior in Diabetes
NCT01363609 ·Status: COMPLETED ·Phase: NA